MRI上脑萎缩性T2病灶体积与残疾进展及继发进展型多发性硬化转化的相关性
这项回顾性研究纳入1612名参与者,随访5年,测量萎缩性T2病灶体积、脑体积变化百分比和脑室体积变化百分比。结果显示,萎缩性T2病灶体积与残疾进展(HR 1.23)及从临床孤立综合征或复发缓解型多发性硬化转化为继发进展型(HR 1.16)独立相关。
要点
- 萎缩性T2病灶体积是残疾进展和继发进展型多发性硬化转化的独立MRI标志物。
- 残疾进展者萎缩性T2病灶体积较未进展者高34.4 mm³(95%CI 17.2–51.5,P<.001)。
- 仅萎缩性T2病灶体积与继发进展型转化相关,脑体积和脑室体积变化无显著关联。
核心结论
- 萎缩性T2病灶体积是提示多发性硬化残疾进展及向继发进展型病程转化的稳健MRI标志物。
研究设计与样本
- 回顾性研究,纳入1612名参与者(2006至2016年招募,随访5年),包括1314例多发性硬化患者、124例临床孤立综合征患者和147名健康对照,测量萎缩性T2病灶体积、脑体积变化百分比和脑室体积变化百分比,残疾进展和继发进展型转化依据标准化指南定义。
关键影像表现/征象
- 残疾进展者较未进展者萎缩性T2病灶体积高34.4 mm³(95%CI 17.2–51.5,d=0.27,P<.001)。
- 残疾进展者脑体积变化百分比为-0.21%(95%CI -0.36%至-0.05%,d=0.19,P=.042),与未进展者差异有统计学意义。
- 残疾进展者与未进展者脑室体积变化百分比无显著差异(0.36%,95%CI -0.93%至1.65%,d=0.04,P=.89)。
诊断标准与关键数值
- 残疾进展者与未进展者相比,萎缩性T2病灶体积差异+34.4 mm³(95%CI 17.2–51.5,P<.001)。
- 继发进展型转化者与未转化者相比,萎缩性T2病灶体积差异+26.4 mm³(95%CI 4.2–56.9,P=.002)。
- Cox回归中,萎缩性T2病灶体积与残疾进展相关(HR 1.23,P<.001),与继发进展型转化相关(HR 1.16,P=.008)。
临床应用与阅片要点
- 阅片时可关注T2病灶被脑脊液空间替代形成的萎缩性T2病灶体积,该指标与残疾进展和继发进展型转化相关。
- 报告多发性硬化MRI时,除常规T2病灶负荷外,可结合萎缩性T2病灶体积评估疾病进展风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Atrophied T2 lesion volume at MRI is an imaging measure that reflects the replacement of T2 lesions by cerebrospinal fluid spaces in patients with multiple sclerosis (MS). Purpose To investigate the association of atrophied T2 lesion volume and development of disability progression (DP) and conversion to secondary progressive MS (SPMS). Materials and Methods This retrospective study included 1612 participants recruited from 2006 to 2016 and followed up for 5 years with clinical and MRI examinations. Accumulation of T2 lesion volume, atrophied T2 lesion volume, percentage brain volume change (PBVC), and percentage ventricular volume change (PVVC) were measured. Disability progression and secondary progressive conversion were defined by using standardized guidelines. Analysis of covariance (ANCOVA) adjusted for age and Cox regression adjusted for age and sex were used to compare study groups and explore associations between MRI and clinical outcomes. Results A total of 1314 patients with MS (1006 women; mean age, 46 years ± 11 [standard deviation]) and 124 patients with clinically isolated syndrome (100 women; mean age, 39 years ± 11) along with 147 healthy control subjects (97 women; mean age, 42 years ± 13) were evaluated. A total of 336 of 1314 (23%) patients developed DP, and in 67 of 1213 (5.5%) the disease converted from clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) to SPMS. Patients with conversion to DP had higher atrophied T2 lesion volume (+34.4 mm3; 95% confidence interval [CI]: 17.2 mm3, 51.5 mm3; d = 0.27; P < .001) and PBVC (-0.21%; 95% CI: -0.36%, -0.05%; d = 0.19; P = .042) but not PVVC (0.36%; 95% CI: -0.93%, 1.65%; d = 0.04; P = .89) or T2 lesion volume change (-64.5 mm3; 95% CI: -315.2 mm3, 186.3 mm3; d = 0.03; P = .67) when compared with DP nonconverters. ANCOVA showed that atrophied T2 lesion volume was associated with conversion from CIS or RRMS to SPMS (+26.4 mm3; 95% CI: 4.2 mm3, 56.9 mm3; d = 0.23; P = .002) but not PBVC (-0.14%; 95% CI: -0.46%, 0.18%; d = 0.11; P = .66), PVVC (+0.18%; 95% CI: -2.49%, 2.72%; d = 0.01; P = .75), or T2 lesion volume change (-46.4 mm3; 95% CI: -460.8 mm3, 367.9 mm3; d = 0.03; P = .93). At Cox regression analysis, only atrophied T2 lesion volume was associated with the DP (hazard ratio, 1.23; P < .001) and conversion to SPMS (hazard ratio, 1.16; P = .008). Conclusion Atrophied brain T2 lesion volume is a robust MRI marker of MS disability progression and conversion into a secondary progressive disease course. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Chiang in this issue.
引用
- Genovese AV, Hagemeier J, Bergsland N, et al. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology. 2019. PMID: 31549947. doi:10.1148/radiol.2019190306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。